Bictegravir, Emtricitabine, and Tenofovir Alafenamide
Medically reviewed by Drugs.com. Last updated on Jul 17, 2019.
(bik TEG ra vir em trye SYE ta been & ten OF oh vir al a FEN a mide)
- Bictegravir Sodium, Emtricitabine, and Tenofovir Alafenamide
- Emtricitabine, Bictegravir, and Tenofovir Alafenamide
- Tenofovir Alafenamide, Bictegravir, and Emtricitabine
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Biktarvy: Bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg
Brand Names: U.S.
- Antiretroviral, Integrase Inhibitor (Anti-HIV)
- Antiretroviral, Reverse Transcriptase Inhibitor, Nucleoside (Anti-HIV)
- Antiretroviral, Reverse Transcriptase Inhibitor, Nucleotide (Anti-HIV)
Bictegravir, an integrase inhibitor, inhibits HIV integrase by binding to the integrase-active site and blocking the strand transfer step of DNA integration. Emtricitabine is a cytosine analogue and tenofovir alafenamide is converted intracellularly to tenofovir (adenosine nucleotide analog) and subsequently phosphorylated by cellular kinases to the active moiety, tenofovir diphosphate. Emtricitabine and tenofovir alafenamide interfere with HIV viral RNA-dependent DNA polymerase activities resulting in inhibition of viral replication.
Bictegravir: By CYP3A enzymes and hepatic glucuronidation mediated by UGT1A1
Emtricitabine: Not significantly metabolized
Tenofovir alafenamide: Converted intracellulary by hydrolysis (non-CYP enzymes) to tenofovir then phosphorylated by cellular kinases to the active moiety, tenofovir diphosphate; minimal extent by CYP3A
Bictegravir: Feces (60.3%), urine (35%); Emtricitabine: Feces (13.7%), urine (70%); Tenofovir alafenamide: Feces (31.7%), urine (<1%)
Time to Peak
Bictegravir: 2 to 4 hours; Emtricitabine: 1.5 to 2 hours; Tenofovir alafenamide: 0.5 to 2 hours
Bictegravir: 17.3 hours; Emtricitabine: 10.4 hours; Tenofovir alafenamide: 0.51 hours (active metabolite, tenofovir diphosphate: 150 to 180 hours [intracellular])
Bictegravir: >99%; Emtricitabine <4%; Tenofovir alafenamide ~80%
Use: Labeled Indications
HIV-1 infection, treatment: Treatment of HIV-1 infection (as a complete regimen) in adults and pediatric patients ≥25 kg as initial therapy in those with no antiretroviral treatment history; or to replace a stable antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) with no history of treatment failure and no known substitutions associated with resistance to the individual components.
Coadministration with dofetilide, rifampin
Canadian labeling: Additional contraindications (not in US labeling): Hypersensitivity to bictegravir, emtricitabine , tenofovir alafenamide, or any component of the formulation; coadministration with St John’s wort
HIV-1 infection, treatment: Oral: One tablet once daily
Refer to adult dosing.
HIV-1 infection, treatment: Note: Products are a fixed-dose combination; use not recommended in other weight groups. Gene mutation and antiretroviral resistance patterns should be evaluated (refer to https://www.iasusa.org for more information) when necessary.
Pediatric patients weighing ≥25 kg: Oral: Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg per tablet): One tablet once daily; in clinical trials, the youngest patients were 6 years of age (HHS [pediatric] 2018)
Oral: Administer with or without food.
Store below 30°C (86°F); dispense in original container.
Acyclovir-Valacyclovir: May increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Acyclovir-Valacyclovir. Monitor therapy
Adefovir: May diminish the therapeutic effect of Tenofovir Products. Adefovir may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Adefovir. Avoid combination
Aminoglycosides: May increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Aminoglycosides. Monitor therapy
Cabozantinib: MRP2 Inhibitors may increase the serum concentration of Cabozantinib. Monitor therapy
Calcium Salts: May decrease the serum concentration of Bictegravir. Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered with calcium salts under fed conditions, but coadministration with or 2 hours after a calcium salt is not recommended under fasting conditions. Consider therapy modification
CarBAMazepine: May decrease the serum concentration of Tenofovir Alafenamide. Avoid combination
Cidofovir: May increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Cidofovir. Monitor therapy
Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. Avoid combination
Cobicistat: May enhance the adverse/toxic effect of Tenofovir Products. More specifically, cobicistat may impair proper tenofovir monitoring and dosing. Monitor therapy
CYP3A4 Inducers (Strong): May decrease the serum concentration of Bictegravir. Management: Rifampin is specifically contraindicated, and the use of carbamazepine, phenytoin, or phenobarbital is not recommended when alternatives are acceptable Monitor therapy
CYP3A4 Inhibitors (Strong): May increase the serum concentration of Bictegravir. Monitor therapy
Diclofenac (Systemic): May enhance the nephrotoxic effect of Tenofovir Products. Management: Seek alternatives to this combination whenever possible. Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose. Consider therapy modification
Dofetilide: Bictegravir may increase the serum concentration of Dofetilide. Avoid combination
Fosphenytoin-Phenytoin: May decrease the serum concentration of Tenofovir Alafenamide. Avoid combination
Ganciclovir-Valganciclovir: Tenofovir Products may increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Tenofovir Products. Monitor therapy
Iron Preparations: May decrease the serum concentration of Bictegravir. Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered with iron preparations under fed conditions, but coadministration with or 2 hours after an iron preparation is not recommended under fasting conditions. Exceptions: Ferric Carboxymaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose. Consider therapy modification
LamiVUDine: May enhance the adverse/toxic effect of Emtricitabine. Avoid combination
MetFORMIN: Bictegravir may increase the serum concentration of MetFORMIN. Monitor therapy
Nonsteroidal Anti-Inflammatory Agents: May enhance the nephrotoxic effect of Tenofovir Products. Management: Seek alternatives to these combinations whenever possible. Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose. Consider therapy modification
Orlistat: May decrease the serum concentration of Antiretroviral Agents. Monitor therapy
OXcarbazepine: May decrease the serum concentration of Tenofovir Alafenamide. Avoid combination
PHENobarbital: May decrease the serum concentration of Tenofovir Alafenamide. Avoid combination
Polyvalent Cation Containing Products: May decrease the serum concentration of Bictegravir. Management: Administer bictegravir under fasting conditions at least 2 hours before or 6 hours after polyvalent cation containing products. Coadministration of bictegravir with or 2 hours after most polyvalent cation products is not recommended. Exceptions: Calcium Acetate; Calcium Carbonate; Calcium Chloride; Calcium Citrate; Calcium Glubionate; Calcium Gluconate; Calcium Lactate; Ferric Citrate; Ferric Maltol; Ferrous Fumarate; Ferrous Gluconate; Ferrous Sulfate; Iron Acetyltransferrin; Polycarbophil; Polysaccharide-Iron Complex; Shark Derivatives; Sodium Feredetate. Consider therapy modification
Primidone: May decrease the serum concentration of Tenofovir Alafenamide. Avoid combination
Rifabutin: May decrease the serum concentration of Tenofovir Alafenamide. Avoid combination
Rifabutin: May decrease the serum concentration of Bictegravir. Avoid combination
RifAMPin: May decrease the serum concentration of Tenofovir Alafenamide. Avoid combination
RifAMPin: May decrease the serum concentration of Bictegravir. Avoid combination
Rifapentine: May decrease the serum concentration of Tenofovir Alafenamide. Avoid combination
Rifapentine: May decrease the serum concentration of Bictegravir. Avoid combination
Sofosbuvir: May increase the serum concentration of Tenofovir Alafenamide. Monitor therapy
St John's Wort: May decrease the serum concentration of Tenofovir Alafenamide. Avoid combination
St John's Wort: May decrease the serum concentration of Bictegravir. Avoid combination
Tipranavir: May decrease the serum concentration of Tenofovir Alafenamide. Avoid combination
Also see individual agents.
>10%: Hepatic: Increased serum bilirubin (12%)
1% to 10%:
Cardiovascular: Increased serum creatine kinase (4%)
Central nervous system: Headache (4% to 5%), abnormal dreams (≤3%), fatigue (2% to 3%), dizziness (2%), insomnia (2%), depression (<2%)
Dermatologic: Skin rash (<2%)
Endocrine & metabolic: Increased LDL cholesterol (2% to 3%)
Gastrointestinal: Diarrhea (3% to 6%), nausea (3% to 5%), increased serum amylase (2%), abdominal pain (<2%), dyspepsia (<2%), flatulence (<2%), vomiting (<2%)
Hematologic & oncologic: Decreased neutrophils (2%)
Hepatic: Increased serum alanine aminotransferase (1% to 2%), increased serum aspartate aminotransferase (1% to 2%)
Frequency not defined: Renal: Increased serum creatinine
<1%, postmarketing, and/or case reports: Angioedema, suicidal ideation, urticaria
ALERT: U.S. Boxed WarningPost treatment acute exacerbation of hepatitis B:
Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of bictegravir/emtricitabine/tenofovir alafenamide.
Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue bictegravir/emtricitabine/tenofovir alafenamide. If appropriate, anti-hepatitis B therapy may be warranted.
Concerns related to adverse effects:
• Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome, resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves disease, polymyositis, Guillain-Barré syndrome, autoimmune hepatitis) later in therapy; further evaluation and treatment may be required.
• Lactic acidosis/hepatomegaly: Lactic acidosis and severe hepatomegaly with steatosis, sometimes fatal, have been reported with the use of nucleoside analogs, alone or in combination with other antiretrovirals. Suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity (marked transaminase elevation may/may not accompany hepatomegaly and steatosis).
• Renal toxicity: Cases of acute renal failure and/or Fanconi syndrome have been reported with use of tenofovir prodrugs; patients with preexisting renal impairment and those taking nephrotoxic agents (including NSAIDs) are at increased risk. Assess serum creatinine, estimated CrCl, urine protein, and urine glucose prior to initiation of therapy and during therapy; in patients with chronic kidney disease, also assess serum phosphorus. Discontinue therapy in patients that develop clinically significant decreases in renal function or evidence of Fanconi syndrome.
• Chronic hepatitis B: [US Boxed Warning]: Severe acute exacerbations of HBV have been reported in patients coinfected with HIV-1 and HBV following discontinuation of antiretroviral therapy. Closely monitor hepatic function with clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue bictegravir/emtricitabine/tenofovir alafenamide therapy. If appropriate, anti-hepatitis B therapy may be warranted, especially in patients with advanced hepatic disease or cirrhosis (post-treatment exacerbation of hepatitis may lead to hepatic decompensation or liver failure). All patients with HIV should be tested for HBV prior to initiation of treatment.
• Hepatic impairment: Use is not recommended in patients with severe hepatic impairment (Child-Pugh class C).
• Renal impairment: Use is not recommended in patients with CrCl <30 mL/minute.
Concurrent drug therapy issues:
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions for more detailed information.
CD4 count, HIV RNA plasma levels; serum creatinine, urine glucose, urine protein (prior to initiation and as clinically indicated during therapy); serum phosphorus in patients with chronic kidney disease; hepatic function tests, bone density (patients with a history of bone fracture or have risk factors for bone loss); testing for HBV is recommended prior to the initiation of antiretroviral therapy. If used as therapy replacement in virologically suppressed patients meeting criteria, additional HIV-1 RNA and regimen tolerability monitoring is recommended to assess potential virologic failure or rebound. Patients with HIV and HBV coinfection should be monitored for several months following therapy discontinuation.
It is not known if bictegravir crosses the placenta. Data collected by the antiretroviral registry related to the use of bictegravir in pregnancy is insufficient to evaluate teratogenicity. Refer to the emtricitabine and tenofovir alafenamide monographs for additional information specific to these components.
The Health and Human Services (HHS) Perinatal HIV Guidelines note data are insufficient to recommend this fixed-dose combination for HIV-infected pregnant females who are antiretroviral-naive, who have had antiretroviral therapy (ART) in the past but are restarting, who require a new ART regimen (due to poor tolerance or poor virologic response of current regimen), who are not yet pregnant but are trying to conceive, or who become pregnant during therapy. Pharmacokinetic studies of bictegravir are not available to make dosing recommendations for pregnant females.
ART is generally recommended for all pregnant females with HIV to keep the viral load below the limit of detection and reduce the risk of perinatal transmission. In general, females who become pregnant on a stable antiretroviral therapy regimen may continue that regimen if viral suppression is effective, appropriate drug exposure can be achieved, contraindications for use in pregnancy are not present, and the regimen is well tolerated. Monitoring during pregnancy is more frequent than in non-pregnant adults. ART should be continued postpartum for all females living with HIV and can be modified after delivery (HHS [perinatal] 2018).
Health care providers are encouraged to enroll pregnant females exposed to antiretroviral medications as early in pregnancy as possible in the Antiretroviral Pregnancy Registry (1-800-258-4263 or http://www.APRegistry.com).
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience diarrhea, nausea, or headache. Have patient report immediately to prescriber signs of kidney problems (urinary retention, hematuria, change in amount of urine passed, or weight gain), signs of liver problems (dark urine, fatigue, lack of appetite, nausea, abdominal pain, light-colored stools, vomiting, or jaundice), signs of lactic acidosis (fast breathing, tachycardia, abnormal heartbeat, vomiting, fatigue, shortness of breath, severe loss of strength and energy, severe dizziness, feeling cold, or muscle pain or cramps), or signs of infection (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about bictegravir / emtricitabine / tenofovir alafenamide
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- En Español
- 75 Reviews
- Drug class: antiviral combinations
- Bictegravir, emtricitabine, and tenofovir
- Bictegravir, Emtricitabine, and Tenofovir Alafenamide
- Bictegravir, emtricitabine, and tenofovir alafenamide (Advanced Reading)
Other brands: Biktarvy